SE0003126D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
SE0003126D0
SE0003126D0 SE0003126A SE0003126A SE0003126D0 SE 0003126 D0 SE0003126 D0 SE 0003126D0 SE 0003126 A SE0003126 A SE 0003126A SE 0003126 A SE0003126 A SE 0003126A SE 0003126 D0 SE0003126 D0 SE 0003126D0
Authority
SE
Sweden
Prior art keywords
treatment
disorder
disorders
methods
relates
Prior art date
Application number
SE0003126A
Other languages
English (en)
Inventor
John Robertson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0003126A priority Critical patent/SE0003126D0/sv
Publication of SE0003126D0 publication Critical patent/SE0003126D0/sv
Priority to JP2002524503A priority patent/JP2004508333A/ja
Priority to EP01961576A priority patent/EP1326616B1/en
Priority to PT01961576T priority patent/PT1326616E/pt
Priority to ES01961576T priority patent/ES2238469T3/es
Priority to AU2001282832A priority patent/AU2001282832A1/en
Priority to US10/398,307 priority patent/US7338948B2/en
Priority to AT01961576T priority patent/ATE291920T1/de
Priority to DE60109799T priority patent/DE60109799T2/de
Priority to PCT/SE2001/001879 priority patent/WO2002020019A1/en
Priority to DK01961576T priority patent/DK1326616T3/da
Priority to HK03108463A priority patent/HK1056120A1/xx
Priority to US11/972,350 priority patent/US20080108597A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
SE0003126A 2000-09-05 2000-09-05 Method of treatment SE0003126D0 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE0003126A SE0003126D0 (sv) 2000-09-05 2000-09-05 Method of treatment
DK01961576T DK1326616T3 (da) 2000-09-05 2001-08-31 Anvendelse af quetiapin til "Attention Deficit Hyperactivity Disorder" eller alvorlige adfærdsforstyrrelser
ES01961576T ES2238469T3 (es) 2000-09-05 2001-08-31 Uso de quetiapina para la hiperactividad con deficit de la atencion o para trastorno de la conducta.
EP01961576A EP1326616B1 (en) 2000-09-05 2001-08-31 Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder
PT01961576T PT1326616E (pt) 2000-09-05 2001-08-31 Utilizacao de quetiapina para o disturbio de defice de atencao com hiperactividade ou disturbio de conduta
JP2002524503A JP2004508333A (ja) 2000-09-05 2001-08-31 クエチアピンの新規な用途
AU2001282832A AU2001282832A1 (en) 2000-09-05 2001-08-31 New use of quetiapine
US10/398,307 US7338948B2 (en) 2000-09-05 2001-08-31 Use of quetiapine
AT01961576T ATE291920T1 (de) 2000-09-05 2001-08-31 Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen
DE60109799T DE60109799T2 (de) 2000-09-05 2001-08-31 Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen
PCT/SE2001/001879 WO2002020019A1 (en) 2000-09-05 2001-08-31 New use of quetiapine
HK03108463A HK1056120A1 (en) 2000-09-05 2003-11-20 Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder.
US11/972,350 US20080108597A1 (en) 2000-09-05 2008-01-10 New Use of Quetiapine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0003126A SE0003126D0 (sv) 2000-09-05 2000-09-05 Method of treatment

Publications (1)

Publication Number Publication Date
SE0003126D0 true SE0003126D0 (sv) 2000-09-05

Family

ID=20280890

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0003126A SE0003126D0 (sv) 2000-09-05 2000-09-05 Method of treatment

Country Status (11)

Country Link
US (2) US7338948B2 (sv)
EP (1) EP1326616B1 (sv)
JP (1) JP2004508333A (sv)
AT (1) ATE291920T1 (sv)
AU (1) AU2001282832A1 (sv)
DE (1) DE60109799T2 (sv)
ES (1) ES2238469T3 (sv)
HK (1) HK1056120A1 (sv)
PT (1) PT1326616E (sv)
SE (1) SE0003126D0 (sv)
WO (1) WO2002020019A1 (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008526839A (ja) * 2005-01-07 2008-07-24 アストラゼネカ・アクチエボラーグ １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
GB0822077D0 (en) * 2008-12-03 2009-01-07 Minster Res Ltd Novel treatments
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US5627178A (en) * 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
JP2004508333A (ja) 2004-03-18
WO2002020019A1 (en) 2002-03-14
US20080108597A1 (en) 2008-05-08
EP1326616A1 (en) 2003-07-16
ATE291920T1 (de) 2005-04-15
AU2001282832A1 (en) 2002-03-22
DE60109799T2 (de) 2006-02-16
PT1326616E (pt) 2005-06-30
ES2238469T3 (es) 2005-09-01
DE60109799D1 (de) 2005-05-04
US20040034010A1 (en) 2004-02-19
HK1056120A1 (en) 2004-02-06
EP1326616B1 (en) 2005-03-30
US7338948B2 (en) 2008-03-04

Similar Documents

Publication Publication Date Title
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
TW200505942A (en) Antibody molecules having specificity for human IL-1β
NO20034056D0 (no) Proliferative sykdommer
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
NO20055741D0 (no) Nye kjemiske forbindelser
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
TNSN04015A1 (en) Combination therapy for the treatment of cancer
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
ATE410235T1 (de) Behandlung von ballastwasser
ATE448779T1 (de) Methode zur behandlung trockener augen und uveitis
EA200400793A1 (ru) Применение ингибиторов обратного захвата норэпинефрина для лечения нарушения познавательной функции
SE0003126D0 (sv) Method of treatment
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE602004019541D1 (de) Cycloalkyläbü kondensierte indole
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE426678T1 (de) Ammoniumsulfat zur aufhebung von inhibitorischen effekten
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE345818T1 (de) S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen.